Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Investigating the Effects and Side Effects of Two Antipsychotic Drugs in the Treatment of Children and Adolescents with Tourette Syndrome: A Semi-experimental Research

Author(s): Atefeh Soltanifar, Raheleh Lashkarnevis, Maliheh Ziaee, Fatemeh Moharari, Roya Samadi, Azadeh Soltanifar and Maedeh Kamrani*

Volume 20, Issue 6, 2023

Published on: 26 June, 2023

Article ID: e090623217825 Pages: 8

DOI: 10.2174/1570163820666230609095720

Price: $65

conference banner
Abstract

Introduction: Due to the high prevalence of Tourette's disorder among children and adolescents and its negative consequences, an appropriate and effective medical treatment with minimal complications is necessary. Therefore, this study was conducted to compare the effects of Aripiprazole and Risperidone on Tourette's disorders in children and adolescents.

Methods: The statistical population of this semi-experimental study was children and adolescents aged seven to eighteen years old. They were diagnosed with Tourette's disorder based on the DSM-V criteria by the clinical interview of a child and adolescent psychiatrist in the child Psychiatry clinic of Ibne- Sina's Psychiatric Hospital (Mashhad-Iran) in 2018. A total of forty participants were selected by the convenience sampling method, and they were randomly divided into two groups treated with medicines, Risperidone or Aripiprazole, for two months. Then, the demographic information questionnaire was completed. The Y-GTSS Scale was completed. The clinical Effect Rating Scale (CGI-Tics Scale) was completed. Calculation of body mass index and medical side effects complications were completed. The evaluation was carried out at the beginning and on the second, fourth, and eighth weeks, and the results were compared. The data were analyzed using SPSS software. 14, descriptive statistics, Chi-square, and variance analysis.

Results: The two groups were homogeneous in terms of demographic variables and body mass index. Despite the positive effect of both medicines, no significant difference was observed among the general scores of such disorders, the overall score of severity, Tourette's recovery, and BMI of these two groups at the intervals and the end of treatments. (p <0.05). Due to the low number of complications reported, statistical comparisons of the medical side effects were not made.

Conclusion: According to the results, the two medicines, Aripiprazole and Risperidone, effectively improved the symptoms of Tourette's disorder and its overall severity. However, there were no significant statistical differences between them. Furthermore, in terms of the medical side effects, the statistical comparison between the two medicines was impossible due to the small number of complications.

Graphical Abstract

[1]
Sadock BJ, Sadock VA, Ruiz P. Comprehensive textbook of psychiatry. (10th ed.), 2017.
[2]
Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: A cross-cultural perspective. J Psychosom Res 2009; 67(6): 475-83.
[http://dx.doi.org/10.1016/j.jpsychores.2009.07.010] [PMID: 19913651]
[3]
Sun N, Tischfield JA, King RA, Heiman GA. Functional evaluations of genes disrupted in patients with Tourette’s disorder. Front Psychiatry 2016; 7: 11.
[http://dx.doi.org/10.3389/fpsyt.2016.00011] [PMID: 26903887]
[4]
Ünal D, Akdemir D. Neurobiology of tourette syndrome. Turk Psikiyatr Derg 2016; 27(4): 275-85.
[PMID: 28046197]
[5]
Kurlan R. Tourette’s syndrome. N Engl J Med 2010; 363(24): 2332-8.
[http://dx.doi.org/10.1056/NEJMcp1007805] [PMID: 21142535]
[6]
Ganos C. Tics and Tourette’s: update on pathophysiology and Tic control. Curr Opin Neurol 2016; 29(4): 513-8.
[http://dx.doi.org/10.1097/WCO.0000000000000356] [PMID: 27310537]
[7]
Nagy P, Bognár E, Farkas L, et al. Clinical characteristics of children with tourette’s syndrome. Psychiatr Hung 2020; 35(1): 37-45.
[PMID: 31854321]
[8]
Rose O, Hartmann A, Worbe Y, Scharf JM, Black KJ. Tourette syndrome research highlights from 2018. F1000 Res 2019; 8: 988.
[http://dx.doi.org/10.12688/f1000research.19542.1]
[9]
Surén P, Bakken IJ, Skurtveit S, et al. Tourette syndrome in children in Norway. Tidsskr Nor Laegeforen 2019; 139(17)
[http://dx.doi.org/10.4045/tidsskr.19.0411]
[10]
Szejko N, Jakubczyk A, Janik P. Prevalence and clinical correlates of self-harm behaviors in Gilles de la Tourette syndrome. Front Psychiatry 2019; 10: 638.
[http://dx.doi.org/10.3389/fpsyt.2019.00638] [PMID: 31543843]
[11]
Rizzo R, Gulisano M. Treatment options for Tic disorders. Expert Rev Neurother 2020; 20(1): 55-63.
[http://dx.doi.org/10.1080/14737175.2020.1698950] [PMID: 31795779]
[12]
Chen CW, Wang HS, Chang HJ, Hsueh CW. Effectiveness of a modified comprehensive behavioral intervention for Tics for children and adolescents with tourette’s syndrome: A randomized controlled trial. J Adv Nurs 2020; 76(3): 903-15.
[http://dx.doi.org/10.1111/jan.14279] [PMID: 31782167]
[13]
Deeb W, Malaty IA, Mathews CA. Tourette disorder and other Tic disorders. Handb Clin Neurol 2019; 165: 123-53.
[http://dx.doi.org/10.1016/B978-0-444-64012-3.00008-3] [PMID: 31727209]
[14]
Gill CE, Kompoliti K. Clinical features of tourette syndrome. J Child Neurol 2020; 35(2): 166-74.
[http://dx.doi.org/10.1177/0883073819877335] [PMID: 31608744]
[15]
Benaroya-Milshtein N, Shmuel-Baruch S, Apter A, Valevski A, Fenig S, Steinberg T. Aggressive symptoms in children with Tic disor-ders. Eur Child Adolesc Psychiatry 2020; 29: 617-24.
[http://dx.doi.org/10.1007/s00787-019-01386-6] [PMID: 31396706]
[16]
Openneer TJC, Tárnok Z, Bognar E, et al. The Premonitory Urge for Tics Scale in a large sample of children and adolescents: Psychometric properties in a developmental context. An EMTICS study. Eur Child Adolesc Psychiatry 2020; 29: 1411-24.
[http://dx.doi.org/10.1007/s00787-019-01450-1] [PMID: 31802271]
[17]
Mustafa S, Joober R, Iyer S, Shah J, Lepage M, Malla A. Early stabilization of weight changes following treatment with olanzapine, risperidone, and aripiprazole: A 12-month naturalistic study of first episode psychosis. J Clin Psychiatry 2019; 80(5): 1087.
[http://dx.doi.org/10.4088/JCP.18m12717]
[18]
Padala PR, Qadri SF, Madaan V. Aripiprazole for the treatment of Tourette’s disorder. Prim Care Companion J Clin Psychiatry 2005; 7(6): 296-9.
[PMID: 16498492]
[19]
Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008; 18(5): 509-15.
[http://dx.doi.org/10.1089/cap.2007.061] [PMID: 18928415]
[20]
Liu Y, Chen Y, Chen H, Liu Z. A control study of aripiprazole and tiapride treatment for Tic disorders in children. Chin J. Contemp Pediatr 2010; 12(6): 421-4.
[21]
Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006; 21(7): 447-53.
[http://dx.doi.org/10.1002/hup.798] [PMID: 17029306]
[22]
Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with Tic disorders. J Child Adolesc Psychopharmacol 2009; 19(4): 441-7.
[http://dx.doi.org/10.1089/cap.2008.0149] [PMID: 19702496]
[23]
Yoo HK, Choi SH, Park S, Wang HR, Jin-Pyo J-P, Kim CY. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with Tic disorders. J Clin Psychiatry 2007; 68(7): 1089-94.
[http://dx.doi.org/10.4088/JCP.v68n0717] [PMID: 17685747]
[24]
Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette’s disorder: An open-label safety and tolerability study. J Child Adolesc Psychopharmacol 2009; 19(6): 623-33.
[http://dx.doi.org/10.1089/cap.2009.0035] [PMID: 20035580]
[25]
Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with Tic disorder: A randomized double blind clinical trial. Child Psychiatry Hum Dev 2014; 45(5): 596-603.
[http://dx.doi.org/10.1007/s10578-013-0427-1] [PMID: 24343476]
[26]
Yoo HK, Lee JS, Paik KW, et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric Tic disorders. Eur Child Adolesc Psychiatry 2011; 20(3): 127-35.
[http://dx.doi.org/10.1007/s00787-010-0154-0] [PMID: 21188439]
[27]
Cox J, Seri S, Cavanna A. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic Tic disorders. Pediatric Health Med Ther 2016; 7: 57-64.
[http://dx.doi.org/10.2147/PHMT.S87121]
[28]
Jeon S, Walkup JT, Woods DW, et al. Detecting a clinically meaningful change in Tic severity in Tourette syndrome: A comparison of three methods. Contemp Clin Trials 2013; 36(2): 414-20.
[http://dx.doi.org/10.1016/j.cct.2013.08.012] [PMID: 24001701]
[29]
Hasanpour-Dehkordi A, Safavi P. AmirAhmadi M. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial. J Adv Pharm Technol Res 2016; 7(2): 43-7.
[http://dx.doi.org/10.4103/2231-4040.177203] [PMID: 27144151]
[30]
Yang C, Yi Q, Zhang L, Cui H, Mao J. Safety of aripiprazole for Tics in children and adolescents. Medicine 2019; 98(22): e15816.
[http://dx.doi.org/10.1097/MD.0000000000015816] [PMID: 31145316]
[31]
Frölich J, Starck M, Banaschewski T, Lehmkuhl G. A drug treatment alternative for Tourette’s syndrome in children and adolescents. Z Kinder Jugendpsychiatr Psychother 2010; 38: 291-8.
[http://dx.doi.org/10.1024/1422-4917/a000049] [PMID: 20617499]
[32]
Cui Y, Zheng Y, Yang Y, Liu J, Li J. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: A pilot study in China. J Child Adolesc Psychopharmacol 2010; 20(4): 291-8.
[http://dx.doi.org/10.1089/cap.2009.0125] [PMID: 20807067]
[33]
Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005; 8(3): 489-90.
[http://dx.doi.org/10.1017/S1461145705005365] [PMID: 15857570]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy